Manufacturer of Controlled Substances; Notice of Registration, 1813-1814 [2010-509]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 8 / Wednesday, January 13, 2010 / Notices
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than February 12, 2010.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: January 6, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–504 Filed 1–12–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances Notice of Registration
srobinson on DSKHWCL6B1PROD with NOTICES
Schedule
VerDate Nov<24>2008
16:51 Jan 12, 2010
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Jkt 220001
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
II
II
II
II
The company plans on manufacturing
the listed controlled substances in bulk
for sale to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Cody
Laboratories to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Cody
Laboratories to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
[FR Doc. 2010–511 Filed 1–12–10; 8:45 am]
By Notice dated August 28, 2009, and
published in the Federal Register on
September 8, 2009, (74 FR 46231), Cody
Laboratories, 601 Yellowstone Avenue,
Cody, Wyoming 82414, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Oxymorphone (9652) ...................
Schedule
Dated: January 6, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
Drug
Drug
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated August 28, 2009, and
published in the Federal Register on
September 8, 2009, (74 FR 46231),
Chemic Laboratories, Inc., 480 Neponset
Street, Building 7, Canton,
Massachusetts 02021, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Cocaine (9041),
a basic class of controlled substance
listed in schedule II.
The company plans to manufacture
small quantities of the above listed
controlled substance for distribution to
its customers for the purpose of
research.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Chemic Laboratories to manufacture the
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
1813
listed basic class of controlled substance
is consistent with the public interest at
this time. DEA has investigated Chemic
Laboratories to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: January 6, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–515 Filed 1–12–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated September 14, 2009,
and published in the Federal Register
on September 18, 2009, (74 FR 47962),
GE Healthcare, 3350 North Ridge
Avenue, Arlington Heights, Illinois
60004–1412, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Cocaine (9041),
a basic class of controlled substance
listed in schedule II.
The company plans to manufacture a
radioactive product used in diagnostic
imaging in the diagnosis of Parkinson’s
Disease and for manufacture in bulk for
investigational new drug (IND)
submission and clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of GE
Healthcare to manufacture the listed
basic class of controlled substance is
consistent with the public interest at
this time. DEA has investigated GE
Healthcare to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
E:\FR\FM\13JAN1.SGM
13JAN1
1814
Federal Register / Vol. 75, No. 8 / Wednesday, January 13, 2010 / Notices
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: January 6, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–509 Filed 1–12–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
srobinson on DSKHWCL6B1PROD with NOTICES
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated August 28, 2009 and
published in the Federal Register on
September 8, 2009, (74 FR 46232),
Noramco Inc., Division of Ortho McNeil,
Inc., 500 Swedes Landing Road,
Wilmington, Delaware 19801–4417,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Noroxymorphone (9668), a basic class of
controlled substance listed in schedule
II.
The company plans to bulk
manufacture the listed controlled
substance as a reference standard for
distribution to its customers which are
analytical laboratories.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Noramco Inc. to manufacture the listed
basic class of controlled substance is
consistent with the public interest at
this time. DEA has investigated
Noramco Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: January 6, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
National Institute of Corrections
Manufacturer of Controlled
Substances; Notice of Registration
Solicitation for a Cooperative
Agreement—Curriculum Development:
Training for Correctional Industries
Directors
By Notice dated August 28, 2009, and
published in the Federal Register on
September 8, 2009, (74 FR 46233),
National Center for Natural Products
Research-NIDA MProject, University of
Mississippi, 135 Coy Waller Lab
Complex, University, Mississippi 38677,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I:
Drug
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
The company plans to cultivate
marihuana for the National Institute on
Drug Abuse for research approved by
the Department of Health and Human
Services.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
National Center for Natural Products
Research-NIDA MProject to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated National Center for Natural
Products Research-NIDA MProject to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: January 6, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–506 Filed 1–12–10; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2010–508 Filed 1–12–10; 8:45 am]
BILLING CODE 4410–09–P
VerDate Nov<24>2008
16:51 Jan 12, 2010
Jkt 220001
I
I
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
AGENCY: National Institute of
Corrections, Department of Justice.
ACTION: Solicitation for a cooperative
agreement.
SUMMARY: The National Institute of
Corrections’ (NIC) Transition and
Offender Workforce Development (T/
OWD) and Academy Divisions are
seeking applications for the
development of a competency based,
blended modality training curriculum
that will provide Correctional Industries
Directors with the knowledge, skills and
abilities needed to set organizational
priorities, identify strategic objectives,
create measurable goals, establish
collaborative partnerships, utilize
current labor market information, and
provide specialized services and
programming that support the offenders’
long term attachment to the labor force.
DATES: Applications must be received
by 4 p.m. EST on Friday, February 12,
2010.
ADDRESSES: Mailed applications must be
sent to: Director, National Institute of
Corrections, 320 First Street, NW., Room
5007, Washington, DC 20534.
Applicants are encouraged to use
Federal Express, UPS, or similar service
to ensure delivery by the due date.
Hand delivered applications should
be brought to 500 First Street, NW.,
Washington, DC 20534. At the front
desk, dial 7–3106, extension 0 for
pickup.
Faxed applications will not be
accepted. Electronic applications can be
submitted via https://www.grants.gov.
FOR FURTHER INFORMATION CONTACT: All
technical or programmatic questions
concerning this announcement should
be directed to Michael Guevara,
Correctional Program Specialist,
National Institute of Corrections. He can
be reached by calling 303–365–4415, or
by e-mail at mguevara@bop.gov.
Questions will be accepted until one
week prior to the application due date.
At this time responses to the questions
will be posted on the NIC Web site.
SUPPLEMENTARY INFORMATION:
Overview: NIC is looking to develop a
curriculum, which follows NIC’s
Instructional Theory Into Practice (ITIP)
model, to be written based on
occupational documentation that
includes a completed DACUM
(Developing A Curriculum) and a
E:\FR\FM\13JAN1.SGM
13JAN1
]]>Agencies
[Federal Register Volume 75, Number 8 (Wednesday, January 13, 2010)]
[Notices]
[Pages 1813-1814]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-509]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated September 14, 2009, and published in the Federal
Register on September 18, 2009, (74 FR 47962), GE Healthcare, 3350
North Ridge Avenue, Arlington Heights, Illinois 60004-1412, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of Cocaine (9041), a basic class
of controlled substance listed in schedule II.
The company plans to manufacture a radioactive product used in
diagnostic imaging in the diagnosis of Parkinson's Disease and for
manufacture in bulk for investigational new drug (IND) submission and
clinical trials.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
GE Healthcare to manufacture the listed basic class of controlled
substance is consistent with the public interest at this time. DEA has
investigated GE Healthcare to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33,
[[Page 1814]]
the above named company is granted registration as a bulk manufacturer
of the basic class of controlled substance listed.
Dated: January 6, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-509 Filed 1-12-10; 8:45 am]
BILLING CODE 4410-09-P
